Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Operating Expenses (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Operating Expenses for 7 consecutive years, with $96.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 24.03% to $96.7 million in Q4 2025 year-over-year; TTM through Nov 2025 was $369.6 million, a 38.15% increase, with the full-year FY2025 number at $369.6 million, up 38.15% from a year prior.
  • Operating Expenses was $96.7 million for Q4 2025 at Nurix Therapeutics, down from $99.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $99.3 million in Q3 2025 to a low of $29.5 million in Q1 2021.
  • A 5-year average of $62.0 million and a median of $58.0 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 92.42% in 2021, then grew 0.51% in 2023.
  • Nurix Therapeutics' Operating Expenses stood at $45.3 million in 2021, then grew by 22.32% to $55.5 million in 2022, then rose by 9.05% to $60.5 million in 2023, then increased by 28.84% to $77.9 million in 2024, then grew by 24.03% to $96.7 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Operating Expenses are $96.7 million (Q4 2025), $99.3 million (Q3 2025), and $92.4 million (Q2 2025).